Top Stories
Duke’s biobanks will give Network Bio access to patient samples linked to years of clinical records, helping train AI models for drug discovery and disease detection.
The combination of its marketed drug Kimmtrak and investigational T-cell engager brenetafusp posted an estimated two-year OS of 70% in metastatic uveal melanoma patients.
The study linked Repatha to a 20% lower risk of heart attacks in patients with atherosclerotic cardiovascular disease and prior statin use.
Eli Lilly's two GLP-1 offerings Zepbound (tirzepatide) and Foundayo (orforglipron) will be available via Hims & Hers' consumer platform.
The collaboration, focused on developing RNA editing candidates for cardiometabolic diseases, was on the rocks after being paused in Nov. last year.
Conference News
Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; topline data expected 2H 2027Novel real-wo...
With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30 ...
KING OF PRUSSIA, PA, UNITED STATES, November 6, 2026 /EINPresswire.com/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using i...
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks...
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at si...
